Clinical Report: Prognostic and Immune Characteristics of KIRC via MAMs

Overview

This study identifies DNM1L as a potential therapeutic target in kidney renal clear cell carcinoma (KIRC) through the analysis of mitochondria-associated membranes (MAMs) and machine learning techniques. The findings suggest that MAMs-related gene expression patterns correlate with clinical outcomes and immune microenvironment characteristics in KIRC patients.

Background

Kidney renal clear cell carcinoma (KIRC) is the most common subtype of renal cell carcinoma, accounting for over 70% of cases. The increasing incidence and challenges in treating metastatic RCC highlight the need for reliable prognostic biomarkers and novel therapeutic targets. Understanding the role of MAMs in KIRC could provide insights into cancer metabolism and potential treatment strategies.

Data Highlights

No numerical data provided in the source material.

Key Findings

• 42 MAMs-related genes were curated and analyzed for expression patterns in KIRC.
• A comprehensive machine learning strategy involving 10 algorithms and 101 combinations was employed to develop a MAMs-based scoring model.
• The MAMs score was associated with clinical parameters and prognostic outcomes in KIRC patients.
• DNM1L was identified as a key gene in the MAMs model, with its knockdown suppressing tumor growth in vitro and in vivo.
• Alterations in MAM-associated proteins may lead to increased resistance to anticancer therapies.

Clinical Implications

The identification of DNM1L as a potential therapeutic target may guide future treatment strategies for KIRC. Additionally, the MAMs-based scoring model could serve as a prognostic tool to better stratify patients and tailor immunotherapy approaches.

Conclusion

This study underscores the importance of MAMs in KIRC and highlights DNM1L as a promising target for further therapeutic exploration. Continued research in this area may enhance treatment outcomes for patients with KIRC.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. The ASCO Post — Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses
5. The ASCO Post — Immunoassay Test May Help Identify Early Kidney Cancer
6. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2025.pdf
7. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial - PubMed
8. Improving mitochondria-associated endoplasmic reticulum membranes integrity as converging therapeutic strategy for rare neurodegenerative diseases and cancer - ScienceDirect